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Abstract Ageing can be characterised by a general
decline in cellular function, which affects whole-body
homoeostasis with metabolic dysfunction—a common
hallmark of ageing. The identification and characterisation
of the genetic pathways involved are paramount to the
understanding of how we age and the development of
therapeutic strategies for combating age-related disease.
Furthermore, in addition to understanding the ageing pro-
cess itself, we must understand the interactions ageing has
with genetic variation that results in disease phenotypes.
The use of model systems such as the mouse, which has a
relatively short lifespan, rapid reproduction (resulting in a
large number of offspring), well-characterised biology, a
fully sequenced genome, and the availability of tools for
genetic manipulation is essential for such studies. Here we
review the relationship between ageing and metabolism
and highlight the need for modelling these processes.
Ageing and disease
There is a clear link between age and susceptibility to a
wide range of diseases [reviewed in (Niccoli and Partridge
2012)] and key among the age-related diseases that are
rising in incidence is diabetes and metabolic syndrome.
Ageing has specific consequences on mammalian physi-
ology, but it also interacts with genetic variation to result in
disease. There are clear genetic influences in the majority
of age-related pathologies, and to fully understand disease,
and how to treat it, we must understand these interactions
and the influence have on the pathogenesis of these dis-
eases (Fig. 1).
Metabolism and ageing are inextricably intertwined:
Reducing calorie intake has been demonstrated in a number
of studies to improve longevity, with some additional
benefits to health (Robertson and Mitchell 2013; Soare
et al. 2014). These nutrient-sensing pathways appear to
modulate ageing as a whole and reducing calorie intake
activates target of rapamycin (TOR), and involves the
sirtuin family of genes (Hall et al. 2013), resulting in an
increased lifespan in several model organisms (Fontana
et al. 2010; Kapahi et al. 2010; Hall et al. 2013). The
intimate relationship between nutrient intake and longevity
is now the subject of extensive investigations to identify
potential health benefits of caloric restriction. However,
whilst there are clear benefits in some model organisms,
the health benefits of caloric restriction are less clear-cut in
primates (Mattison et al. 2012; Colman et al. 2014), and
thus the general health benefits to humans are still debat-
able. The level of calorie intake and its influence on ageing
and health highlights the close link between metabolism
and ageing, and given the range of changes in metabolism
with ageing (Barzilai et al. 2012). It is clear that this link
needs to be understood in greater detail. The interrela-
tionship between the ageing process(es) and metabolism is
emphasised by the increased longevity in mice with a
deletion of the insulin receptor (IR) substrate 1 gene
(Selman et al. 2008).
A clear distinction must be made between increasing
lifespan and health span; the former being an increase
survival time and the latter a concept reflecting the con-
cerns of health care professionals and researchers whose
major concern is disease. Increased longevity is not a
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panacea against all ills and long-lived individuals still
succumb to common age-related disorders (Andersen et al.
2012). The increase in lifespan that the human race has
experienced over the last few decades to centuries resulted
in a greatly increased disease burden and thus we still need
to address pathologies on an individual basis to improve
the condition of elderly patients and alleviate symptoms of
these diseases.
Insulin secretion, action and diabetes
Type 2 diabetes is the major metabolic disease associated
with ageing populations, with incidence of disease typi-
cally occurring after 40 years and peaking between 60 and
74 years of age. The pathogenesis of type 2 diabetes is
characterised by peripheral insulin resistance and impaired
insulin secretion. Type 2 diabetes itself increases the risk
for multiple other age-related diseases such as cancer,
stroke, atherosclerosis, cardiovascular diseases (CVD),
Parkinson’s disease, nonalcoholic fatty liver disease (NA-
FLD) and Alzheimer’s disease (AD). Ageing in turn can
pre-dispose to diabetes and impaired glucose tolerance
(IGT) through effects on insulin secretion and insulin
action. Many factors contribute to this observed decrease in
insulin secretion in ageing, including age-associated loss of
Sirt1-mediated glucose-stimulated insulin secretion (GSIS)
(Ramsey et al. 2008), decreased beta-cell sensitivity to
circulating incretins (Chang and Halter 2003), and age-
associated decrease in mitochondrial function and
increased oxidative stress.
Defects in insulin secretion with ageing have been
demonstrated in both rodents and humans. Rodent models
have been utilised to demonstrate elegantly the inability of
older animals to increase insulin secretion in response to
increased insulin demand, which is driven by insulin
resistance (van der Heide et al. 2006). Insulin secretion in
the beta cell is the result of the uptake (via GLUT2) and
metabolism of glucose [via Glucokinase (GCK)], resulting
in the generation of ATP (mainly in the mitochondria),
closure of the ATP-sensitive potassium channels leading to
membrane depolarisation and influx of calcium, a rise in
intra-cellular calcium levels results in exocytosis of insulin
granules. The age-related changes in this process and their
relevance to IGT and type 2 diabetes will be discussed
briefly.
Sensing and uptake of glucose by the beta cell are the
first step in insulin secretion; glucose uptake in the beta cell
is facilitated by the glucose transported GLUT2 with
numerous studies demonstrating GLUT2 is essential for
glucose uptake. Loss of pancreatic b-cell GLUT2 expres-
sion in humans is associated with hyperglycaemia and
impaired GSIS (Ohtsubo et al. 2005). Age-associated
decrease in the expression of GLUT2 has been demon-
strated in rodent models (Ihm et al. 2007); however,
reduced GLUT2 by itself cannot explain the reduction in
GSIS in islets of Goto–Kakizaki (GK) rats (Ohneda et al.
1993). After uptake, glucose undergoes oxidation resulting
in the generation of ATP, which in turn is required for
insulin release. The oxidation of glucose is initiated by
GCK which catalyses the first and rate-limiting reaction in
glycolysis. Gene expression studies have shown GCK
levels were significantly increased in healthy aged rats
(Frese et al. 2007) suggesting a potential mechanism to
overcome age-associated glucose intolerance and insulin
resistance.
Increased ATP/ADP ratio in b-cells results in depolar-
isation of beta-cell membrane and extracellular Ca? influx
into the b-cell. These changes are mediated through ATP-
sensitive KATP channels and voltage-gated Ca
? channels.
Studies in islets from 24-month-old rats compared to
3-month-old islets showed that raising the glucose con-
centration from 3 to 5.6 and 16.7 mM had no effect on K?
efflux and significantly diminished net uptake of Ca2?.
These data suggest that the decreased insulin secretory
response during old age is in part due to inadequate inhi-
bition of K? efflux and diminished net uptake of Ca2?
(Ammon et al. 1987). Elevation of cytosolic-free Ca2?
concentrations is required for the process of exocytosis of
insulin which is the final step of insulin secretion. Insulin is
Fig. 1 Major changes observed in important metabolic tissues due to
ageing and their contributions to age-related disease
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stored in large dense core vesicles (LDCVs) or insulin
granules and is released via exocytosis—a multistage
process involving vesicle trafficking, docking and fusion
with the plasma membrane.
Three main factors are involved with regulation of b-cell
mass, proliferation and apoptosis of b-cells and islet neo-
genesis (differentiation of a progenitor cell or transdiffer-
entiation of pancreatic non-b-cell to b-cell). However, b-
cell mass is mainly controlled by the balance of prolifer-
ation and apoptosis. It has been shown that age correlates
with decreased proliferation and enhanced sensitivity to
glucose-induced b-cell apoptosis (Maedler et al. 2006). In
cultured islets from young (2–3 month old) rats, increasing
glucose concentrations decreased b-cell apoptosis and
increased b-cell proliferation, whereas in old (7–8 month
old) islets, increasing concentrations of glucose resulted in
a linear increase in b-cell death and a decrease in prolif-
eration. b-cell mass can slowly expand in adult rodents in
response to increased insulin requirements or during
pregnancy (Parsons et al. 1992), with b-cell proliferation
and the capacity of the b-cell to regenerate declining with
age in mice (Tschen et al. 2009). Young rodents respond to
a high-fat diet (HFD) by increasing b-cell mass maintain-
ing glucose homoeostasis, whereas old mice by contrast do
not display increases in b-cell mass or proliferation and
become diabetic. Islet neogenesis that occurs during
embryonic development and in very early post-natal life
can lead to b-cell mass expansion and has been shown to be
important in increasing b-cell mass in the adult during
periods of increased insulin demand such as obesity (Butler
et al. 2003). Although the potential for b-cell replication
appears to decline substantially with age, the rate of islet
neogenesis is not affected by ageing in humans (Reers et al.
2009).
Insulin action is the ability of insulin to bind to its
receptors, the net physiological effect of which is (1) the
regulation of glucose homoeostasis through increased
glucose uptake and decreased hepatic glucose production
(via decreased gluconeogenesis and glycogenolysis) and
(2) increase in lipid synthesis in adipocytes and the atten-
uation of the release of free fatty acid (FFA) from tri-
glycerides in fat. Insulin resistance results when circulating
levels of insulin are insufficient to regulate these process
appropriately and it has been well documented that ageing
is associated with a decline in insulin action (DeFronzo
1981; Rowe et al. 1983; Chen et al. 1988) which is thought
to directly contribute to the high prevalence of IGT and
type 2 diabetes with age (Enzi et al. 1986; Harris et al.
1987). Increase of visceral fat (VF) levels with ageing has
been implicated in insulin resistance, CVD and type 2
diabetes. Several studies suggest that VF increases
throughout the lifespan of adults (independent of race or
sex) and that increase is independent of increases in body
weight (Borkan et al. 1983, 1985; Enzi et al. 1986; Kotani
et al. 1994). Experiments in which VF was extracted from
20-month-old Fischer 344 Brown Norway (FBN) rats
prevented the progressive decrease in insulin action and
delayed the onset of diabetes (Gabriely et al. 2002).
Impaired insulin action also leads to a marked increase
in the rate of lipogenesis in adipose tissue and activation of
hepatic gluconeogenesis in spite of already high circulating
plasma glucose levels. This increased rate of lipolysis
increases circulating FFA levels which exacerbates insulin
resistance in the whole body. Lowering FFA levels over-
night normalises insulin sensitivity in obese non-diabetic
individuals and significantly improves insulin sensitivity in
obese diabetic patients (Santomauro et al. 1999). High FFA
levels may provide a unifying mechanism for insulin
resistance in obesity, type 2 diabetes, lipodystrophy and
ageing (Samuel et al. 2010).
Insulin resistance in the central nervous system (CNS)
has been show to play an important role in regulating
whole-body glucose metabolism. Like peripheral tissues
(such as muscle, adipose tissue and liver), insulin signal-
ling molecules such as the IR and its substrates (IRS) are
universally expressed in the brain. Ablation of the IR in the
CNS alone results in a more severe impairment in
peripheral glucose homoeostasis that mice-lacking IR in
the peripheral tissues (Koch et al. 2008). Studies have
shown that intra-cerebroventricular administration of
insulin was more effective at reducing food intake and
body weight in 3-month-old rats than in 8- and 24-month-
old rats, indicating the development of hypothalamic
insulin resistance with age in Wistar rats (Garcia-San
Frutos et al. 2007). An ageing-associated increase in cen-
tral and peripheral insulin resistance could therefore con-
tribute to diabetes.
Ageing and obesity
Obesity is one of the major risk factors for diabetes and
metabolic disease, and fat distribution alters during the
ageing process. Obesity is defined by body mass index
[BMI = weight (kg)/height (m2)], overweight is described
as a BMI: 25–29.9 kg/m2 and obese as a BMI [ 30 kg/m2
and is closely related to both percentage of body fat and
total body fat (WHO 2011). Obesity leads to metabolic
imbalances, reduces life span and accelerated cellular
processes similar to those of ageing (Ahima 2009), such as
deterioration of the structure and function of organs asso-
ciated with oxidative stress, genetic instability and the
disturbance of homeostatic pathways. 20 % of cancers in
the US over the last 25 years have been predicted to be
caused by weight gain and obesity (Calle et al. 2003). In
European (Dykens and Will 2007) populations, the causal
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link between obesity and endometrial and oesophageal
cancers has been suggested to be as high as 37 % (Inter-
national Agency for Research on Cancer 2002). Worldwide
obesity has nearly doubled since 1980, WHO figures show
in 2008, more than 1.4 billion adults, 20 and older, were
overweight. Of these over 200 million men and nearly 300
million women were obese. 65 % of the world’s population
lives in countries where overweight and obesity kill more
people than underweight, and more than 40 million chil-
dren under the age of five were overweight in 2011. 44 %
of the diabetes burden, 23 % of the ischaemic heart disease
burden and between 7 and 41 % of certain cancer burdens
are attributable to overweight and obesity (WHO 2011).
Body composition changes dramatically throughout life,
total body weight increases until middle age (30–50 years)
and slowly declines thereafter (Lutz et al. 2008), total fat
mass peaks in early or late middle age (40–70 years)
resulting in an increase in percentage of body fat (Kuk
et al. 2009). By advanced old age ([85 years), adipose
tissue is redistributed from subcutaneous to visceral depots
plus ectopic sites such as muscle, liver and bone marrow
with important metabolic complications. Manipulating
adipose tissues abundance and distribution has profound
effects on life span and age-related disease onset. Adipose
tissue is not solely responsible for energy storage, it also
has important immune, endocrine, homeostatic and thermal
actions (Bray and Ryan 2006), with different fat deposits
acting in distinct roles. Different fat depots undergo
changes at differing rates with ageing, leading to fat
redistribution from subcutaneous to visceral depots (Cart-
wright et al. 2007). Abdominal fat increases, whilst sub-
cutaneous fat (especially from the lower body) decreases.
Fat also accumulates in or around the heart, skeletal muscle
and bone marrow, and increased VF is independently
associated with mortality, insulin resistance, diabetes,
CVD, cerebrovascular disease, heart failure, cognitive
impairment and hepatic steatosis. The combination of
glucose intolerance, insulin resistance, central obesity,
dyslipidemia and hypertension constitutes metabolic syn-
drome (Morley 2004).
Loss of subcutaneous fat may contribute to reduced
leptin-mediated b-oxidation of fatty acids, since leptin is
produced primarily by subcutaneous fat with little pro-
duction by VF (Kirkland and Dobson 1997). Reduced b-
oxidation of fatty acids together with reduced capacity of
subcutaneous fat to store triglycerides may contribute to
increasing circulating FFAs in old age. High FFA levels
lead to lipotoxicity, with cellular stress response activation,
and apoptosis (Eckel et al. 2005) redistribution of excess
circulating FFAs may in turn contribute to insulin resis-
tance and therefore be a central mechanism of metabolic
syndrome. In the pancreas, FFAs result in insulinopenia as
they are highly toxic to pancreatic b-cells (Bays et al.
2008). FFAs also generate endothelial cell dysfunction and
impair vasodilation additionally contributing to hyperten-
sion. In old age, even pre-adipocytes become susceptible to
lipotoxicity, at concentrations at which pre-adipocytes
from younger animals remain viable. These cells from
older animals accumulate small lipid droplets characteristic
of lipotoxicity and die due to apoptosis (Guo et al. 2007).
Ageing mice will lead to moderate obesity as in general
mice are cage-bound, are relatively sedentary and have
food ad libitum. However, common models used to study
obesity are mice fed on a HFD or genetically modified
mice predisposed to obesity such as the ob/ob mice (Mayer
and Jones 1953). HFD generally consists of *40 % fat
content and induces rapid weight gain, and ob/ob mice
become obese within a few weeks age (Wang et al. 2014).
In both cases, mice are young and obese and thus missing
important aspects of an ageing physiology. Recent studies
have demonstrated a difference in gene expression in fat
deposits between young, obese mice and old, obese mice
(Liu et al. 2013).
Mitochondrial degeneration
The primary function of mitochondria is to produce ATP
through the process of oxidative phosphorylation and is
unique among the cellular organelles as they contain their
own genetic information mtDNA, a double-stranded cir-
cular molecule of 16.5 kb encoding 13 proteins, 22 transfer
RNAs (tRNAs) and 2 ribosomal RNAs in mammals. The
13 mtDNA-encoded proteins are all components of the
respiratory chain (RC) or the ATP synthase. Proper mito-
chondrial function is required for normal metabolism and
health. Among many contributing factors to ageing is the
gradual decline of mitochondrial function with age leading
to progressive tissue damage via oxidative stress. Muta-
tions in mitochondrial DNA result in a variety of pheno-
types including myopathies, neuropathies, diabetes, as well
as premature signs of ageing and reduced lifespan (Larsson
2010; Patti and Corvera 2010; Lee and Wei 2012). Mito-
chondrial dysfunction occurs at an organ-specific level in
many age-related diseases including type 2 diabetes and
obesity. In both rodents and humans, both obesity and
diabetes are associated with reduced expression of mtDNA
and reduced levels of oxidative phosphorylation in muscle,
liver and adipose tissues (Larsson 2010), with caloric
restriction increasing mitochondrial biogenesis and main-
taining mitochondrial function (Lee and Wei 2012).
There is evidence that the number of mtDNA mutations
increases with age in humans; for example, deletions in
mtDNA have been observed in the aged human CNS,
skeletal muscle and hepatocytes (Yen et al. 1991; Corral-
Debrinski et al. 1992; Fayet et al. 2002), whereas mtDNA
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point mutations accumulate in ageing colonic crypts
(Taylor et al. 2003). These mutations may arise as a con-
sequence of unrepaired DNA damage, for example, dam-
age caused by ROS or replication errors during normal
mtDNA synthesis (Larsson 2010). The replication of
mtDNA occurs independently of the cell cycle; therefore, a
particular mtDNA molecule may be replicated many times
or not at all as a cell divides (Clayton 1982). Experimental
data supporting a role for mtDNA mutations in ageing were
only recently obtained by the generation of mtDNA
mutator mice (Trifunovic et al. 2004; Kujoth et al. 2005).
The mtDNA mutator mice are homozygous for a knock-in
mutation that leads to the expression of a proofreading-
deficient catalytic subunit of mtDNA polymerase (Pol-
gAmut), the expression of which causes excessive mtDNA
mutagenesis with the formation of 3 different forms of
mtDNA mutations: random point mutations, linear mole-
cules with large deletions and molecules containing mul-
timers of the control region.
The mtDNA mutator mice display a range of phenotypes
similar to those observed with natural ageing, including
kyphosis, anaemia, hair loss, alopecia, greying of the hair,
hearing loss, cardiomyopathies, reduced fertility, weight loss
and a shortened lifespan. Evidence strongly suggests that the
high mtDNA mutation load in mtDNA mutator mice leads to
the synthesis of RC subunits with amino acid substitutions
that cause instability of the RC complexes (Edgar et al.
2009). mtDNA deletor mice which express a mutant-domi-
nant version of twinkle, the replicative DNA helicase in
mitochondria, accumulate low levels of large-scale mtDNA
deletions. Although these mice show progressive RC dys-
function and late-onset mitochondrial myopathy, they do not
display a progeroid phenotype and have a normal lifespan.
This would suggest that accumulation of mtDNA deletions
and progressive RC dysfunction may not be sufficient to
accelerate ageing (Tyynismaa et al. 2005).
Although mitochondrial dysfunction has been shown to
directly affect ageing, cellular and metabolic alterations also
contribute to the ageing process by promoting secondary
changes in mitochondrial energy production or mitochon-
drial biogenesis. Therefore, ageing phenotypes have been
linked to aberrant mitochondrial biogenesis caused by
impaired retrograde signalling regulated by nuclear genes
and factors dependent of mitochondrial metabolism, for
example, ATP, Ca2?, ROS, NO, NAD?/NADH. Insulin/
IGF-1 signalling (IIS) and TOR signalling pathways are the
two main nutrient-sensing pathways that have been linked to
the regulation of lifespan. There is evidence that PGC-1a
(Mootha et al. 2003; Anderson et al. 2008; Choi et al. 2008)
and SIRT1 (Finley and Haigis 2009) are involved in the
regulation of mitochondrial metabolism and lifespan. It
should be noted, however, that PGC-1a does not regulate
basal mitochondrial biogenesis, but is also involved in
increasing mitochondrial function on demand by activating
the expression of certain nuclear-encoded genes (Lee et al.
2002). There is a need for future studies to determine the
relative contributions of mitochondrial dysfunction, cellular
bioenergetic deficiency or changes in mitochondrial ROS
production (affecting oxidative damage and signalling) to
different age-related diseases. Mitochondrial dysfunction is
increasingly implicated in the aetiology of drug-induced
toxicities. Members of diverse drug classes undermine
mitochondrial function, and routine screens need to be
incorporated within the drug-development process to mea-
sure mitochondrial toxicity. Assays for mitochondrial
function, cell models that better report mitochondrial
impairment, and new animal models that more faithfully
reflect mitochondrial dysfunction in particular ageing are
required. See review Dykens and Will 2007. The Harwell
metabolic ageing screen may produce potentially important
models for use in drug toxicity screening.
Inflammaging
As discussed a general consequence of ageing is obesity,
although environmental factors such as diet and activity
also play a significant role as well in the amassing of fat
mass with age. Generally with age there is an accumulation
of VF (Folsom et al. 1993) which is a risk factor for several
age-related diseases. The removal of VF is beneficial to
insulin resistance (Barzilai et al. 1999; Gabriely et al. 2002)
and longevity (Muzumdar et al. 2008). Increased adiposity,
particularly VF, has been associated with an increased
production of inflammatory cytokines (Sepe et al. 2011)
such as TNF-a and MCP-1. These inflammatory cytokines
are thought to be produced by pre-adipocytes (Harkins
et al. 2004; Chung et al. 2006) and increased macrophage
infiltration of adipose tissue is observed with ageing. In
addition to the increased inflammatory environment asso-
ciated with VF, the senescence associated secretory profile
(SASP) (Salama et al. 2014) contributes to an increased
inflammatory milieu as part of the ageing physiology of
mammals. The consequences of an increased systemic
inflammation are far reaching as inflammation contributes
to the pathophysiology of many age-related diseases such
as osteoarthritis and neurodegenerative disease. Thus, the
aetiology of changes in the distribution of adipose tissue
during ageing and the subsequent inflammaging are
important factors in age-related disease.
Modelling age-related disorders
Model organisms have made an immeasurable contribution
to our understanding of genetic contributions to disease and
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the resultant pathogenesis, and will continue to do so.
Paramount among the model organisms has been the
mouse, primarily because of the genetic tools that have
been created and the homology of its biology to humans.
However, the majority of mouse models are acute or early
onset with significant pathology within a few months or
even weeks and do not possess an aged physiology. The
ageing process will impact on disease, and thus despite the
clinical challenges we face being ageing population with
late onset or chronic pathologies, many of the models used
to study disease and in pre-clinical studies do not reflect the
true nature of disease.
In order to address the challenges that health services
are now facing worldwide with an ageing population, and
to better understand the interactions between genetic
lesions and the ageing mammalian physiology, it is nec-
essary to place mutations in an ageing context. HFD,
infection and altered light–dark samples are examples of
challenges that have helped identify novel mutations
resulting in disease phenotypes (Nolan et al. 2000; Bacon
et al. 2004; Cook et al. 2006; Godinho et al. 2007; Georgel
et al. 2008). It is clear that substantial changes occur within
the mammalian physiology during the ageing process and
that these can result in, or contribute to, disease (Niccoli
and Partridge 2012). To develop treatments and interven-
tions, we must understand these interactions and the only
way to do this is by ageing mutant mice, using the ageing
physiology as a challenge to reveal mutations that result in
age-related pathologies. This is often done on an individual
basis in specific disease areas such as cancer and autoim-
munity but has not been attempted as part of a forward
genetics screen before. In addition to age-related disease,
using age-challenged mutant mice will reveal the primary
and secondary effects of chronic disease over time.
The large-scale phenotype-driven screens, exemplified
by ENU mutagenesis and the international knock-out
mouse programmes (Acevedo-Arozena et al. 2008; Adams
et al. 2013), are discovery platforms that have been emi-
nently successful in identifying genetics lesions that result
in a phenotype, thus defining novel disease-associated
pathways and assigning novel functions to genes. By taking
a broad-based phenotype-driven approach of mutant mice,
no assumptions are made about the effects of a particular
mutation and novel functions and phenotypes can therefore
be associated to genes. ENU-based screens are particularly
powerful because they generate point mutations, better
modelling the genetic variation seen in humans, and can
result in a wide variety of effects on protein function, even
isolating different functional domains. Confirmation of a
genetic basis of outliers is achieved by mapping of muta-
tions, thus eliminating natural variation in phenotypes and,
whilst successful, these are primarily early onset screens.
We argue that to improve our modelling of age-related
disease and to highlight genetic lesions that interact with an
ageing physiology to result in age-related disease, it is
necessary to carry out such phenotype-driven screens using
ageing as a challenge. In addition to age-related disease,
using age-challenged mutant mice will reveal the primary
and secondary effects of chronic disease over time.
Metabolism is a particularly suitable area for such studies
as outlined above; there are many suitable and high
throughput screens that will reveal phenotypes. Not only
are primary metabolic disorders relatively easy to detect
using glucose and insulin tolerance tests, fasted glucose
levels and body composition screens, but also co-morbid-
ities such as diabetic nephropathy and retinopathy can be
screened for in mice using clinical chemistry analysis and
visual acuity screens. Additionally, as the opportunity for
exercise within standard caging conditions is limited, in
general aged mice become obese. Thus, aged mice are
doubly challenged by age and obesity, all too familiar
condition in patients. Whilst progeroid diseases model an
early ageing phenotype, these do not necessarily recapitu-
late the plethora of age-related pathologies.
Metabolic and diabetic phenotyping in the ageing
mouse
We are now undertaking an age-challenged phenotype-
driven screen to identify genes and pathways that result in
age-related pathologies using established phenotype-driven
protocols (Nolan et al. 2000; Rastan et al. 2004; Acevedo-
Arozena et al. 2008) with an ageing challenge. Whilst
primarily focussed on mutants revealing gene function that
contributes to disease, there is also the potential to identify
mutations that are advantageous and protect against the
consequences of ageing. Lifetime studies are confounded
by expense but a detailed phenotypic pipeline may reveal
mutations preventing obesity or other adverse conditions
such as ageing and thus may represent mutations resulting
in health benefits (Selman et al. 2008, 2009).
In order to address the lack of suitable models of age-related
metabolic disease in particular type 2 diabetes and its associ-
ated complications mice from the Harwell Ageing Screen
(HAS), a G3 recessive ENU mutagenesis screen [ageing G3
pedigrees to 18 months of age (Fig. 2)] has incorporated a
specific metabolism screen. Males (approximately 50/pedi-
gree) are tested in a longitudinal study with body composition,
clinical biochemistry markers and glucose tolerance followed
over the lifespan of the animals. Phenodeviants within pedi-
grees are SNP mapped to identify candidate regions and the
causative mutation identified by whole-genome generation
sequencing (WGS) of the founder G1 male. Gene identifica-
tion without inheritance testing is paramount to the quick
identification of causative genes in an aged mouse model.
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Body composition is measured with Echo MRI at 3, 6,
12 and 18 months, early time points are included to iden-
tify early onset obesity models which can be followed over
the progression of disease and to identify onset of meta-
bolic disease over the lifespan of the mouse. As expected
fat mass increases with age, however, potential advanta-
geous body composition genes can be identified in pedi-
grees where mice remain lean. Females in each cohort can
additionally be tested if a body weight phenotype is iden-
tified within the males, to give additional statistical power.
Body composition is expressed as absolute lean and fat
mass in grams and can be used to identify mice with
increased lean mass as well as increased fat mass. Data can
also be expressed as percentage fat/lean mass to compen-
sate for any observed differences in body size.
Fasted clinical chemistry analysis from tail bleeds is
performed at 4, 7 13 and 18 (terminal) months of age.
Routinely tests for fasted glucose and fructosamine (glucose
homoeostasis), total cholesterol and triglycerides (lipid
profile), ALT (liver function) and creatinine (kidney func-
tion) are performed at 4, 7, and 13 months, with a full
biochemical screen performed on the larger terminal sam-
ple. Pedigrees with significantly elevated plasma glucose
and/or fructosamine additionally undergo intra-peritoneal
glucose tolerance (IPGTT) testing at 5, 8 and 14 months of
age, with fasted plasma insulin levels also measured.
Additional secondary phenotyping tests can be added to the
screen if necessary in order to measure additional metabolic
parameters, for example, whole-body oxygen consumption
(Oxymax, CLAMs), food intake and activity measured and
urine collected. Additionally, all mice with elevated plasma
glucose enter vision screening. Additional biochemical tests
can also be added to the primary screen for pedigrees with
suspected renal or liver disease.
Summary
Ageing results in a series of defined physiological effects
that impact on metabolism and has direct effects on other
important processes either directly or indirectly resulting in
disease. To better understand the pathogenesis of disease, it
is important to incorporate the ageing physiology into
studies and more importantly into models of disease.
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